Loading...
•
Sep 30, 2023
Nuvectis Pharma Q3 2023 Earnings Report
Reported financial results for the third quarter of 2023 and provided an update on recent business progress.
Key Takeaways
Nuvectis Pharma reported its third quarter 2023 financial results, with a net loss of $5.9 million and cash, cash equivalents, and short-term investments of $22.1 million. The company is advancing the development programs of NXP800 and NXP900, with preliminary data from the NXP800 Phase 1b study expected in 1Q 2024.
Advanced the development programs of NXP800 and NXP900.
Expect to report preliminary data from the NXP800 Phase 1b study in 1Q 2024.
FDA granted NXP800 Orphan Drug Designation for the treatment of Cholangiocarcinoma.
Initiated the dose escalation part of Phase 1 study for NXP900 in patients with advanced solid tumors.